In March 2026 the FDA approved Wegovy HD — semaglutide at 7.2 mg, three times the 2.4 mg maintenance dose that has been the standard since Wegovy launched. It exists for a specific group of patients: people who reached the maximum standard dose, tolerated it well, and plateaued short of their goal. It is not a starting dose and it is not a shortcut.
Who Wegovy HD is for
- →Patients already at 2.4 mg semaglutide who tolerate it without significant GI effects
- →Those who plateaued before reaching a clinically meaningful target
- →People who want to stay on semaglutide rather than switch to tirzepatide
Why a higher dose at all
GLP-1 weight loss is dose-dependent up to a point. In the semaglutide trials, higher doses produced greater average reductions, and the 2.4 mg maintenance dose was selected as the balance between efficacy and tolerability across a trial population — not as a biological ceiling.
Some patients sit above that average tolerability curve. They reach 2.4 mg, feel fine, and then stop losing weight while still well short of a clinically useful result. Historically the options were to accept the plateau or switch to tirzepatide.
Wegovy HD adds a third option: stay on the molecule that is working and push the dose. For patients who specifically do well on semaglutide — including those who tried tirzepatide and tolerated it worse — that matters.
The tolerability trade-off is real
GLP-1 side effects are dose-dependent. Tripling the maintenance dose means the nausea, vomiting, diarrhea, and constipation risks scale with it. Patients who found 2.4 mg manageable but not comfortable are unlikely to enjoy 7.2 mg.
The other consideration is what happens on the way down. Appetite tends to return quickly after discontinuation at any dose, and the effect is more pronounced the higher you were. If you escalate to 7.2 mg, plan for a taper rather than a stop.
Questions to ask before escalating
- • Is the plateau actually a plateau, or have four weeks not yet passed at 2.4 mg?
- • Is protein intake adequate, and is there any resistance training happening?
- • Has sleep, alcohol intake, or a new medication changed recently?
- • Would switching to tirzepatide be a better use of the next escalation?
- • What will the higher dose cost, and does insurance cover it at this strength?
Rule out the ordinary explanations first
Most plateaus are not dose problems. Weight loss slows as body mass falls because a smaller body burns fewer calories — that is arithmetic, not treatment failure. A plateau at month eight after 15% loss is expected physiology.
The other common cause is lean mass loss. If a meaningful fraction of what you lost was muscle, resting metabolic rate falls further than it otherwise would. The fix there is protein and resistance training, not more medication. Escalating the dose on a patient losing muscle makes the underlying problem worse.
Bottom line
Wegovy HD is a legitimate option for a narrow group: patients doing well on 2.4 mg semaglutide who have genuinely stalled short of their goal. It is not a first-line dose and it is not the answer to a plateau that has an ordinary explanation.
If you are weighing this against switching molecules, read our semaglutide vs tirzepatide comparison first.